Search Results

Site Search

A Test in Focus Archives - Page 3 of 10 - Insights

Skip to Content MayoACCESS MayoLINK...

Addiction rehabilitation monitoring - Insights

Encompassing comprehensive profiles, confirmatory testing, and interpretive results reporting, addiction rehabilitation monitoring at Mayo Clinic Laboratories supports patients affected by substance use disorder in their rehabilitation and...

Preeclampsia - Insights

Our serum test is the first preeclampsia-specific test that can be used to stratify patients into low- or high-risk categories, indicating whether a patient is at risk for developing preeclampsia with severe features.

A Test in Focus Archives - Page 8 of 10 - Insights

Skip to Content MayoACCESS MayoLINK...

Testing Archives - Insights

Skip to Content MayoACCESS MayoLINK...

Women's health - Insights

Our suite of preeclampsia, prenatal, breast and gynecological cancer, and other testing has been developed in collaboration with clinical leaders in a variety of women’s health specialties to provide accurate, actionable results.

Nonradioactive assay helps diagnose heparin reaction - Insights

Rajiv Pruthi, M.B.B.S., explains how Mayo Clinic Laboratories’ serotonin release assay achieves high sensitivity and specificity while avoiding the use of radioactive materials. Serotonin release testing is an important tool in the...

Novel biomarkers added to movement disorders profile - Insights

Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' expanded movement disorders panel better identifies autoimmune conditions to guide appropriate treatment.

Melanoma panel provides more tumor information - Insights

In this test specific episode of the "Answers From the Lab" podcast, Ruifeng (Ray) Guo, M.D., Ph.D., explains how Mayo Clinic Laboratories' comprehensive melanoma panel better informs prognosis and treatment.

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) - Insights

Divyanshu (Div) Dubey, M.B.B.S., describes Mayo Clinic Laboratories' new diagnostic test for CIDP, or chronic inflammatory demyelinating polyneuropathy. The new test detects two antibodies — NF155 and CNTN1 — to enhance diagnosis and guide...